ASCO '23 Entrees
OncoPharm
00:00
Axesell CAR-T in Refractory Large B-Cell Lymphoma
Only about 24% of patients in this study had received Darrad 2-map at the time of their most recent progression. We are seeing that here in these cat markers. So very strong evidence for Axesell CAR-T in early relapse or refractory large B-cell lymphoma. And this brings me to Cartitude 4 which is a Silta cell or standard care maybe in quotes in little bit refractory multimiolum. No overall survival improvement shown here.
Transcript
Play full episode
